vs
CARLISLE COMPANIES INC（CSL）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是CARLISLE COMPANIES INC的1.1倍（$1.1B vs $1.1B），CARLISLE COMPANIES INC净利率更高（12.1% vs -127.8%，领先139.9%），百利高同比增速更快（-2.5% vs -4.0%），百利高自由现金流更多（$148.6M vs $-73.0M），过去两年百利高的营收复合增速更高（1.3% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
CSL vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.1倍
$1.1B
营收增速更快
PRGO
高出1.5%
-4.0%
净利率更高
CSL
高出139.9%
-127.8%
自由现金流更多
PRGO
多$221.6M
$-73.0M
两年增速更快
PRGO
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.1B |
| 净利润 | $127.7M | $-1.4B |
| 毛利率 | 34.5% | 32.6% |
| 营业利润率 | 17.1% | -116.0% |
| 净利率 | 12.1% | -127.8% |
| 营收同比 | -4.0% | -2.5% |
| 净利润同比 | -10.9% | -3093.9% |
| 每股收益（稀释后） | $3.10 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLPRGO
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.4B | $1.1B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B |
净利润CSLPRGO
| Q1 26 | $127.7M | — | ||
| Q4 25 | $127.4M | $-1.4B | ||
| Q3 25 | $214.2M | $7.5M | ||
| Q2 25 | $255.8M | $-8.4M | ||
| Q1 25 | $143.3M | $-6.4M | ||
| Q4 24 | $162.8M | $-44.4M | ||
| Q3 24 | $244.3M | $-21.0M | ||
| Q2 24 | $712.4M | $-108.4M |
毛利率CSLPRGO
| Q1 26 | 34.5% | — | ||
| Q4 25 | 33.8% | 32.6% | ||
| Q3 25 | 36.0% | 36.1% | ||
| Q2 25 | 37.3% | 34.4% | ||
| Q1 25 | 35.2% | 37.6% | ||
| Q4 24 | 36.1% | 33.9% | ||
| Q3 24 | 38.6% | 37.2% | ||
| Q2 24 | 39.2% | 37.0% |
营业利润率CSLPRGO
| Q1 26 | 17.1% | — | ||
| Q4 25 | 16.8% | -116.0% | ||
| Q3 25 | 21.8% | 7.0% | ||
| Q2 25 | 23.1% | 4.3% | ||
| Q1 25 | 16.8% | 4.5% | ||
| Q4 24 | 19.9% | 10.0% | ||
| Q3 24 | 23.7% | 7.4% | ||
| Q2 24 | 26.0% | -2.5% |
净利率CSLPRGO
| Q1 26 | 12.1% | — | ||
| Q4 25 | 11.3% | -127.8% | ||
| Q3 25 | 15.9% | 0.7% | ||
| Q2 25 | 17.6% | -0.8% | ||
| Q1 25 | 13.1% | -0.6% | ||
| Q4 24 | 14.5% | -3.9% | ||
| Q3 24 | 18.3% | -1.9% | ||
| Q2 24 | 49.1% | -10.2% |
每股收益（稀释后）CSLPRGO
| Q1 26 | $3.10 | — | ||
| Q4 25 | $3.06 | $-10.23 | ||
| Q3 25 | $4.98 | $0.05 | ||
| Q2 25 | $5.88 | $-0.06 | ||
| Q1 25 | $3.20 | $-0.05 | ||
| Q4 24 | $3.76 | $-0.32 | ||
| Q3 24 | $5.25 | $-0.15 | ||
| Q2 24 | $14.84 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $2.9B |
| 总资产 | — | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSLPRGO
| Q1 26 | $771.3M | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $432.1M | ||
| Q2 25 | $68.4M | $454.2M | ||
| Q1 25 | $220.2M | $409.9M | ||
| Q4 24 | $753.5M | $558.8M | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.7B | $542.8M |
总债务CSLPRGO
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益CSLPRGO
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.8B | $2.9B | ||
| Q3 25 | $2.0B | $4.4B | ||
| Q2 25 | $2.1B | $4.5B | ||
| Q1 25 | $2.2B | $4.4B | ||
| Q4 24 | $2.5B | $4.3B | ||
| Q3 24 | $2.8B | $4.6B | ||
| Q2 24 | $3.0B | $4.5B |
总资产CSLPRGO
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $8.5B | ||
| Q3 25 | $6.5B | $10.1B | ||
| Q2 25 | $5.5B | $10.1B | ||
| Q1 25 | $5.5B | $9.8B | ||
| Q4 24 | $5.8B | $9.6B | ||
| Q3 24 | $6.5B | $11.2B | ||
| Q2 24 | $6.7B | $10.4B |
负债/权益比CSLPRGO
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $148.6M |
| 自由现金流率自由现金流/营收 | -6.9% | 13.4% |
| 资本支出强度资本支出/营收 | 2.7% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $924.8M | $145.1M |
8季度趋势，按日历期对齐
经营现金流CSLPRGO
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $175.4M | ||
| Q3 25 | $426.9M | $51.7M | ||
| Q2 25 | $287.1M | $75.9M | ||
| Q1 25 | $1.8M | $-64.5M | ||
| Q4 24 | $370.6M | $312.6M | ||
| Q3 24 | $312.8M | $42.2M | ||
| Q2 24 | $183.4M | $9.5M |
自由现金流CSLPRGO
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | $148.6M | ||
| Q3 25 | $393.4M | $29.8M | ||
| Q2 25 | $258.3M | $56.7M | ||
| Q1 25 | $-27.2M | $-90.0M | ||
| Q4 24 | $334.0M | $274.9M | ||
| Q3 24 | $293.5M | $15.1M | ||
| Q2 24 | $158.5M | $-18.9M |
自由现金流率CSLPRGO
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | 13.4% | ||
| Q3 25 | 29.2% | 2.9% | ||
| Q2 25 | 17.8% | 5.4% | ||
| Q1 25 | -2.5% | -8.6% | ||
| Q4 24 | 29.7% | 24.2% | ||
| Q3 24 | 22.0% | 1.4% | ||
| Q2 24 | 10.9% | -1.8% |
资本支出强度CSLPRGO
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | 2.4% | ||
| Q3 25 | 2.5% | 2.1% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.3% | 3.3% | ||
| Q3 24 | 1.4% | 2.5% | ||
| Q2 24 | 1.7% | 2.7% |
现金转化率CSLPRGO
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | — | ||
| Q3 25 | 1.99× | 6.89× | ||
| Q2 25 | 1.12× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 2.28× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 0.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
| CCM | $758.0M | 72% |
| CWT | $294.0M | 28% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
